Sami Labs Ltd., health science multinational, has initiated
the contract farming for medicinal plants. The company would
provide technical expertise, facilitate loans and insurance
cover for the crops by entering a buy-back agreement with
company started backward integration in 1999, and today
has more than 4000 hectares of land under medicinal plant
have started with the cultivation of coleus forskohlii used
globally for lean body mass management properties. Cardiovascular
and orthopaedic care remain areas of focus for us to further
identify and cultivate medicinal plants in India. Sami's
intellectual process for active ingredient isolation and
properties enhancement will make a significant difference
to the current plant-based healthcare market," Dr Muhammed
Majeed, Chairman and Managing Director, Sami Labs Limited
Labs' has invested Rs 6.crore in its R&D facility located
at Bangalore which has a strength of over 100 scientists.
In the area of biotech research in probiotics it is expected
to rollout products by the end of 2004. With an active patent
regime, the company hopes to infuse significant R&D
funds in its pursuit of developing new products.
company's three new active ingredients -Tetrahydrocurcuminoids
(THC), Coleus oil and ZeaLutien have been approved for the
dermatology, infective and geriatric ophthalmology markets.
The three active ingredients in nutraceuticals and cosmeceuticals
formulations have a combined estimated potential market
size of Rs 20 crore.
Labs now has a total of international 27 patents - 9 approved,
3 allowed and 15 pending.
Labs has so far invested close to Rs 60 crore in four production
units at Bangalore, Singasandra, Kunigal and Mysore. The
company is targeting Rs. 100 crore turnover for its formulations
business in India by the close of 2006.